Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at


Showing results filtered by:
January 16, 2018

NIAID makes many resources available to researchers, such as reagents, model organisms, and tissue samples. Now it’s even easier to find these resources on our site using the Resources for Researchers feature.

January 11, 2018

A new study suggests that influenza infection may enhance some white blood cells’ ability to defend against secondary bacterial infections.

January 3, 2018

International field research poses many challenges to NIAID researchers, but that hasn’t stopped a team from returning to Jordan year after year to study Middle East respiratory syndrome coronavirus (MERS-CoV).

December 19, 2017

Forty years on, survivors of the first Ebola outbreak provide new insights to researchers.

December 15, 2017

A new study offers insights into the immune cell defects that occur in Chediak-Higashi syndrome, a rare genetic disease. Their findings also suggest a potential strategy to develop treatments for this complex syndrome, which is characterized by immune deficiency, predisposition to bleeding, recurring infections and neurological disorders.

December 4, 2017

Dr. Erica Ollmann Saphire, director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), will deliver the 2017 Joseph J. Kinyoun Memorial Lecture on Tuesday, December 5, at 3 p.m. in the Lipsett Amphitheater, in Building 10 of the main NIH campus in Bethesda, Maryland.

November 28, 2017

To make additional HIV prevention options a reality, NIAID supports research on a variety of innovative, long-acting HIV prevention products that could be inserted in the vagina, injected or implanted from once a month to once a year by people who commit to use them on an ongoing basis. These products include a vaginal ring that also delivers contraception.

November 21, 2017

NIH-funded researchers are developing and testing HIV prevention products that may become alternatives to a daily pill.

November 20, 2017

For a visual trek through several species of ticks, check out NIAID’s Tick Pics and Flicks—a collection of photographs and video footage of the diverse arachnids known to carry pathogens that cause illnesses such as Lyme disease, Rocky Mountain Spotted Fever, tularemia and more.

November 17, 2017

Bacterial infections that resist antibiotics are a major problem in the United States. In 2015, the U.S. government launched the National Action Plan for Combating Antibiotic-Resistant Bacteria. Guided by the plan, NIAID and other NIH components work with government, academic, and industry partners on a wide range of projects aimed at understanding and controlling antibiotic resistance. To mark this year’s Antibiotic Awareness Week, November 13-19, we highlight a few of these efforts.

November 14, 2017

Daily antiretroviral therapy can reduce the amount of HIV in the blood to levels that are undetectable with standard tests. Staying on treatment is crucial to keep the virus suppressed. NIAID-supported research has demonstrated that achieving and maintaining a “durably undetectable” viral load (the amount of HIV in the blood) not only preserves the health of the person living with HIV, but also prevents sexual transmission of the virus to an HIV-negative partner.

November 13, 2017

In 2014, as the Ebola outbreak escalated, NIAID collaborated with pharmaceutical company GlaxoSmithKline on NIAID-planned clinical trials to test Ebola vaccine candidates. Their collaboration exemplifies the flexibility and creativity of the NIAID Technology Transfer and Intellectual Property Office, who developed unique and expedited agreements to facilitate the development of an Ebola vaccine.

November 6, 2017

We should all be thankful to have some histamine in our bodies. This chemical messenger helps our brains stay alert, lets our stomachs dissolve food and powers our immune systems to root out and kill infectious parasites.

November 3, 2017

A team of U.S. and Liberian scientists began a large study in Liberia, West Africa to examine how genes affect a person’s response to the Ebola virus. It remains unclear why some infections are asymptomatic and others are fatal, or why some people rapidly clear the infection and others remain in treatment for weeks. Investigators predict that genetic differences could influence these outcomes.

October 25, 2017

Haunted houses, ghastly ghouls, spooky spirits and… frightening food allergies? Halloween can be a stressful time for families managing food allergies. Many popular candies contain peanuts, tree nuts, milk, eggs and other potentially allergenic foods. Reading food labels carefully can help ensure a safe and happy Halloween for everyone.

October 19, 2017

NIAID-funded scientists have found that a new Zika vaccine candidate can protect pregnant mice and their fetuses, as well as male mice and monkeys, with just one dose.

October 11, 2017

“There is real value in experimental odysseys,” says Thomas A. Waldmann, M.D., of the National Cancer Institute.

The NIH Distinguished Investigator celebrated a new leg of one such journey this summer. In June, colleague Michael J. Lenardo, M.D., an investigator at the National Institute of Allergy and Infectious Diseases, published his finding of a genetic cause and potential treatment for a subset of the gastrointestinal disease Waldmann had discovered in 1961. Dr. Lenardo, who Dr. Waldmann recruited to the NIH more than two decades ago, will join Dr. Waldmann to give a Clinical Center Grand Rounds lecture on their discoveries in Masur Auditorium in Building 10 on November 15, 2017.

October 4, 2017

A short animation explains how HIV hijacks the cellular protein alpha-4 beta-7 to home to the gut and establish infection in this organ system, which harbors one of the richest populations of HIV target cells in the body.

September 27, 2017

The fever, fatigue, muscle and headache caused by influenza (flu) can make even the healthiest person feel miserable for days. For more vulnerable people, such as the very young or the elderly, flu can be fatal. Although vaccination is recommended and can help protect against flu infection, there is a need for effective therapies to combat illness caused by the flu virus.

September 18, 2017

Today marks the 10th National HIV/AIDS and Aging Awareness Day. This annual observance brings attention to the unique social and health-related challenges of older people living with and at risk for HIV. NIAID supports and collaborates on research that aims to both understand and mitigate long-term complications of HIV for men and women aging with HIV.

August 28, 2017

Findings from a pair of NIAID-funded studies in zebrafish shed light on how nerve damage is initiated in leprosy and suggest a potential target for the development of strategies to prevent tuberculosis and other mycobacterial diseases.

August 25, 2017

In a new study, researchers describe immune profiles measured prior to vaccination that may predict a person’s antibody response to the seasonal flu vaccine. Their findings also indicate that immune states that predict good vaccine responses in young adults may be associated with poorer responses in older people.

August 21, 2017

Vaccine could provide broad protection against all of these illnesses, as well as other mosquito-borne diseases.

August 21, 2017

Understanding disease carriers---called vectors---is a vital part of learning to control and treat infectious disease. Mosquitoes can transmit malaria, Zika virus, dengue, yellow fever, chikungunya, West Nile Virus, and many other diseases to people, making them one of the deadliest animals on the planet. That is why they are a key focus of NIAID’s research efforts.

August 18, 2017

It’s easy for people to overlook the importance of fast, reliable diagnostic tests in scientific research. Most often, ill patients focus on what treatment is available for them to recover. But without a timely and accurate diagnosis, physicians won’t know the most optimal treatment to provide.

August 14, 2017

NIAID researchers have developed a new method for visualizing in great detail the distribution of cell types in complex tissues, like tumors. The method, called Clearing-enhanced 3D microscopy, or Ce3D, may help researchers evaluate how well immunotherapies target hard-to-treat cancers without many of the limitations associated with related, earlier methods that are currently in use. The findings were described online today in the Proceedings of the National Academy of Sciences.

August 11, 2017

In recent years, multidrug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis (TB) has become increasingly common—and difficult to treat. A new study funded by NIAID reveals that by unravelling the TB bacteria’s DNA and testing it for certain mutations, researchers were able to estimate to what extent the bacteria are resistant to fluoroquinolones, a class of powerful antibiotics typically used to treat TB.

August 8, 2017

NIAID’s intramural research program has begun an innovative training opportunity that aligns lab groups more than 2,000 miles apart that have complementary interests.

July 21, 2017

Have you ever heard about a research finding and thought, “What does that mean?” New observations and discoveries continually contribute to the ever-expanding body of scientific knowledge that ultimately guides medical practice. NIAID Video SNiPs are quick summaries for science lovers and scientists that explain how an incremental advance can provide fresh insights, affect disease outcomes, and improve public health.

July 21, 2017

Like many branches of medicine, immunology can seem to have a complex language of its own describing how the body protects against and fights off infection. Now, you can sort through the dense terminology of the immune system by boning up on some basics in NIAID’s new, illustrated immunology glossary.

July 21, 2017

Ensuring a durable end to the HIV pandemic will require a safe and effective HIV vaccine. A whiteboard video explains how an HIV vaccine could be developed, while focusing on a vaccine currently being tested in a large, NIAID-funded clinical trial in South Africa called HVTN 702.

July 17, 2017

Each May, NIAID-funded researchers descend on the beaches of Delaware Bay in New Jersey to screen migratory shorebirds for the flu. Through this work, they are learning more about how influenza viruses spread and evolve.

February 1, 2017

Read the report and recommendations on a possible Zika virus human challenge study.

January 10, 2017

View the meeting summary from the joint WHO and NIAID/NIH conference on Zika Virus vaccine development.

May 18, 2016

Development of a safe and effective preventive HIV vaccine remains to realizing a durable end to the HIV/AIDS pandemic.

April 19, 2016

First-Line Treatment of TB for Drug-Sensitive TB. Tuberculosis, which results from an infection with Mycobacterium tuberculosis, can be cured with a combination of first-line drugs taken daily for several months. Shown here are the four drugs in the standard regimen of first-line drugs. Also shown are the dates these four drugs were discovered—all more than 40 years ago.

April 1, 2016

NIAID Study Clarifies Role of Enzyme Previously Linked to Allergic Lung Disease. Acidic mammalian chitinase, or AMCase, an enzyme present in humans and other mammals, plays a key role in initiating protective immune responses against certain parasitic gut infections, a new NIAID study shows. The findings in mice suggest that AMCase, which had previously been implicated in allergic lung disease, is critical for defense against gastrointestinal infections with parasitic worms called helminths. The scientists report their results online in Nature Immunology on April 4, 2016.